The MaxDiscovery™ Human IL-15 ELISA Test Kit is designed for quantitative determination of the concentration of human IL-15 in serum, plasma, and cell culture supernatant. Human interleukin 15 (IL-15) is a protein of 114 amino acids after cleavage of a 48 amino acid signal peptide. An alternative splice form of IL-15 has also been identified with an identical mature sequence, but a shorter signal sequence. Interestingly, the shorter prepeptide is not secreted and may represent a functional intracellular molecule. In addition, a membrane-bound form of IL-15 has also been reported, which may be an important physiological form of the molecule. Human IL-15 has 97% and 73% amino acid sequence identity with simian and mouse IL-15, respectively. Both human and simian IL-15s are active on mouse cells. IL-15 is a novel cytokine that shares many biological properties with IL-2. Originally identified in media conditioned by a monkey kidney epithelial cell line (CVI/EBNA) based on its mitogenic activity on the mouse T cell line (CTLL-2), IL-15 was independently discovered as a cytokine produced by a human adult T-cell leukemia cell line (HuT-102) that stimulated T cell proliferation and was designated IL-T . High-affinity cell surface receptors for IL-15 have been detected on a variety of cells including T cells, B cells, and NK cells as well as on non-lymphoid cells. The IL-15 receptor is composed of three molecules; an IL-15 specific a-chain of 237 amino acids, plus a ß-chain and ?-chain that is shared by the receptor system for IL-2. The a-chain binds IL-15 with high affinity. It shows 54% amino acid sequence identity with mouse IL-15 R and exists in multiple alternatively spliced forms. Although the IL-15 receptor is composed of 3 chains, IL-15 will signal through a dimer and the ß?-chain itself may have multiple functions. IL-15 has biological activities similar to IL-2 and has been shown to stimulate the growth of natural killer cells, activated peripheral blood T lymphocytes, tumor infiltrating lymphocytes (TILs), and B cells. In addition, IL-15 has also been shown to be a chemoattractant for human blood T lymphocytes and to induce both lymphokine-activated killer (LAK) activity in NK cells and the generation of cytolytic effector cells. IL-15 apparently also has effects on cells not involved in immune responses. Skeletal muscle cells express IL-15 and IL-15 R mRNAs and respond to the addition of IL-15.
Cytoskeleton Crew Findings confirm sugar's role in helping cancers survive by changing cellular architecture.Biomarker for Recurring HPV-Linked Oropharyngeal Cancers A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University. Valvena, GSK Sign New R&D Collaboration Valneva to supply process development services for EB66® -based Influenza vaccines. Light Signals from Living Cells Fluorescent protein markers delivered under high pressure.Cellular 'Relief Valve' A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.Genomic Signature Shared by Five Types of Cancer National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer. Cat Stem Cell Therapy Gives Humans Hope By the time Bob the cat came to the UC Davis veterinary hospital, he had used up most of his nine lives. Crowdfunding the Fight Against Cancer From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
New Biomarker to Assess Stem Cells Developed A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.A Better Model for Parkinson's Scientists at EPFL solve a longstanding problem with modeling Parkinson’s disease in animals. Using newfound insights, they improve both cell and animal models for the disease, which can propel research and drug development.